Follow on Google News News By Tag * Generics Market * Generics Products * Generics Companies * Generics Health * Generics Product Analysis * Generics Manufacturing * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News |  World Generics Market, 2008-2013Visiongain is proud to announce the release of the brand new report "World Generics Market". The global generic pharmaceuticals market was worth over $100bn in 2007, with market growth noticeably higher that that of the overall pharmaceutical market.
By: Visiongain Ltd. The generics market remains a major growth area in the global healthcare market. That growth has been partly driven by cost-containment in several national healthcare sectors, with governments seeking to promote the use of generic products over higher-priced originator products. The global generic pharmaceuticals market was worth over $100bn in 2007, with market growth noticeably higher that that of the overall pharmaceutical market. Our new report - World Generics Market, 2008-2013 - will help you to understand the key developments in this sector and their significance, from the present looking forward. The report provides valuable commercial information on this exciting sector, one that no pharmaceutical company or related organisation can afford to ignore. Over the period 2008 to 2013, visiongain foresees the generic market to sustain its strong current growth, with exciting new developments to be driven by the wave of blockbuster drugs approaching patent expiry. This report - World Generics Market, 2008-2013 - provides details of these drugs and potential generics revenues. The study also identifies the therapeutic areas that will face the highest levels of competition from generic substitutes from 2008 to 2013. Our report examines the global generics market and industry critically, with in-depth analysis, especially market forecasting and qualitative analysis of market drivers and restraints. The result is a comprehensive market-based report with detailed analysis and informed opinion. Why you should buy this report In particular, World Generics Market, 2008-2013 concentrates on the following essential aspects of the generics market and industry: • Discussion of key issues affecting the global generics market and the wider pharmaceutical market/industry • Why governments and healthcare organisations - including private insurers - are increasingly opting for generic medicines; we provide country-specific information there • Discussion of drivers and opportunities in the generics sector • Discussion of restraints and threats in the generics sector • Sales forecasts from 2008-2013 for the global generics market and leading national generics markets - US, Japan, Germany, France, UK, Spain, Italy • Discussion of developing generics markets, especially China, India and Russia, with major industrial developments covered. Despite the potentially great opportunities to be harnessed by generics companies in both developed and developing countries, there remain marked obstacles to be overcome. While many generics companies are becoming larger and more innovative, originator drugs companies - especially top-10 pharma companies - are generally prepared for the threat from generics, having developed strategies to minimise the effects of sales erosion. Still, there are large potential losses in sales occurring currently - and likely to continue in the years ahead - as one blockbuster drug after another faces direct and indirect generic competition. Certainly, the commercial opportunities for dynamic generics companies are great. Similarly, the cost-saving opportunities for both public and private healthcare providers worldwide are significant. By purchasing this report, you will be better able to appreciate those major developments in the global pharmaceutical market, with many stakeholders affected. Companies Listed Abbott Actavis Alcon Labs Alkem Allergan Apotex Astellas AstraZeneca Aventis Barr Bayer Bayer Schering Berlin-CH/Menarini Boehringer Ingelheim Bristol-Myers Squibb Centre for Studying Health System Change Cipla Daiichi Sankyo Dr Reddy's Eli Lilly European Free Trade Association (EFTA) European Generic Medicines Association (EGA) European Medicines Agency (EMEA) Forest Labs Fresenius Gedeon Richter GlaxoSmithKline Graceway HLJ Haerbin HN.Tongyongsanyang International Monetary Fund Johnson & Johnson Janssen Japanese Generic Pharmaceutical Manufacturers Association (JGPMA) Japanese Ministry of Health, Labour & Welfare (MLHW) Jiangsu YangZijiang JS LYG Hengrui JS Yangzijiang FTY Krka Lek Lupin Labs M.S.D.-Hangzhou Mallinckrodt Menarini Merck & Co Merck KGaA Mylan National Coalition on Health Care National Medical Expenditure (NME) NIchi-Iko Nicholas Piramal Novartis Nycomed Pfizer Pharmstandard Ranbaxy Ratiopharm Roche Sandoz Sanofi-Aventis Sanofi-Syn.M- Sanovil Sawia Servier SH.Asia Pioneer PH Shandong Qilu FTY Stada Sun Pharma Taiyo Takeda Tawo Teva The Medicines Company UCB UK National Health Service (NHS) US Food and Drug Administration (FDA) US Generic Pharmaceutical Association (GPhA) Wal-Mart Watson World Bank World Trade Organisation Agreement on Trade-Related Aspects of Intellectual Property Rights (WTO TRIPS) Wyeth Zydus Cadila Visiongain ltd. 4th Floor, BSG House, 226-236 City Road, London EC1V 2QY United Kingdom Telephone: +44 (0) 20 7336 6100 Fax: +44 (0) 20 7549 9930 info@visiongainglobal.com Or Visit at: http://www.visiongain.com/ Or http://www.visiongain.com # # # Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
